Krystal Biotech (KRYS) EPS (Weighted Average and Diluted) (2020 - 2026)

Krystal Biotech has disclosed EPS (Weighted Average and Diluted) across 7 years of filings, most recently posting $1.83 for Q1 2026.

• EPS (Weighted Average and Diluted) for Q1 2026 came in at $1.83, up 52.5% year-over-year; the trailing twelve-month figure through Mar 2026 was $7.48 (up 79.38% YoY), and the FY2025 annual result was $6.84, up 128.0% from the prior year.
• EPS (Weighted Average and Diluted) came in at $1.83 for Q1 2026 at Krystal Biotech, up from $1.7 in the prior quarter.
• In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $2.79 in Q3 2023 to a low of -$1.99 in Q1 2022.
• The 5-year median for EPS (Weighted Average and Diluted) is $0.53 (2024), against an average of $0.37.
• Across the five-year window, EPS (Weighted Average and Diluted) sank 168.92% in 2022 and soared 3900.0% in 2025, its largest moves.
• Krystal Biotech's EPS (Weighted Average and Diluted) stood at -$1.25 in 2022, then jumped by 124.8% to $0.31 in 2023, then soared by 393.55% to $1.53 in 2024, then advanced by 11.11% to $1.7 in 2025, then rose by 7.65% to $1.83 in 2026.
• The last three EPS (Weighted Average and Diluted) figures came in at $1.83 (Q1 2026), $1.7 (Q4 2025), and $2.66 (Q3 2025), per Business Quant data.